HC Wainwright Downgrades Mainz Biomed (NASDAQ:MYNZ) to Neutral

HC Wainwright lowered shares of Mainz Biomed (NASDAQ:MYNZ) from a buy rating to a neutral rating in a research report sent to investors on Monday, Marketbeat.com reports.

Mainz Biomed Stock Performance

Shares of NASDAQ:MYNZ opened at $0.21 on Monday. Mainz Biomed has a 52 week low of $0.19 and a 52 week high of $1.79. The firm has a 50 day simple moving average of $0.26 and a 200 day simple moving average of $0.40.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.